Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites

Anahit Ghochikyan, Mikayel Mkrtichyan, Dmitri Loukinov, Gregory Mamikonyan, Svetlana D. Pack, Nina Movsesyan, Thomas E. Ichim, David H. Cribbs, Victor V. Lobanenkov, Michael G. Agadjanyan

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Brother of the regulator of imprinted sites (BORIS) was previously described as a transcription factor for epigenetic reprogramming the expression of which is strictly confined to germ cells of adult testes but is aberrantly activated in the vast majority of neoplasiic cells. Considering the critical role of BORIS in cancerogenesis and the fact that its expression pattern may preclude thymic tolerance, we generated DNA- and protein-based mouse BORIS antitumor vaccines using a non-DNA-binding version of the BORIS molecule. Clinical use of BORIS as a vaccine Ag would require that certain safety concerns be met. Specifically, administration of the functional BORIS protein would hypothetically pose a risk of BORIS accelerating the progression of cancer. To alleviate such safety concerns, we have developed vaccines based on the BORIS molecule lacking the DNA-binding zinc fingers domain. To enhance anti-BORIS cellular immune responses, we used a standard molecular adjuvant approach. It consisted of plasmids encoding murine IL-12 and IL-18 for a DNA-based vaccine and conventional Th1 type adjuvant, Quil A, for a protein-based vaccine. Both DNA- and protein-based vaccines induced Ag-specific CD4+ T cell proliferation with Th1 and Th2 cytokine profiles, respectively. Protein-based, but not DNA-based, BORIS vaccine induced a significant level of Ab production in immunized animals. Importantly, potent anticancer CD8+-cytotoxic lymphocytes were generated after immunization with the DNA-based, but not protein-based, BORIS vaccine. These cytolytic responses were observed across a wide range of different mouse cancers including mammary adenocarcinoma, glioma, leukemia, and mastocytoma.

Original languageEnglish (US)
Pages (from-to)566-573
Number of pages8
JournalJournal of Immunology
Volume178
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Testicular Neoplasms
Immunization
Vaccines
T-Lymphocytes
Antigens
Neoplasms
DNA
Proteins
Mastocytoma
Safety
Interleukin-18
DNA Vaccines
Zinc Fingers
Interleukin-12
Epigenomics
Germ Cells
Cellular Immunity
Glioma
Testis
Leukemia

ASJC Scopus subject areas

  • Immunology

Cite this

Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. / Ghochikyan, Anahit; Mkrtichyan, Mikayel; Loukinov, Dmitri; Mamikonyan, Gregory; Pack, Svetlana D.; Movsesyan, Nina; Ichim, Thomas E.; Cribbs, David H.; Lobanenkov, Victor V.; Agadjanyan, Michael G.

In: Journal of Immunology, Vol. 178, No. 1, 01.01.2007, p. 566-573.

Research output: Contribution to journalArticle

Ghochikyan, A, Mkrtichyan, M, Loukinov, D, Mamikonyan, G, Pack, SD, Movsesyan, N, Ichim, TE, Cribbs, DH, Lobanenkov, VV & Agadjanyan, MG 2007, 'Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites', Journal of Immunology, vol. 178, no. 1, pp. 566-573. https://doi.org/10.4049/jimmunol.178.1.566
Ghochikyan, Anahit ; Mkrtichyan, Mikayel ; Loukinov, Dmitri ; Mamikonyan, Gregory ; Pack, Svetlana D. ; Movsesyan, Nina ; Ichim, Thomas E. ; Cribbs, David H. ; Lobanenkov, Victor V. ; Agadjanyan, Michael G. / Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. In: Journal of Immunology. 2007 ; Vol. 178, No. 1. pp. 566-573.
@article{6f5f60f46ecc4c8e8799e45bb7dc1fc5,
title = "Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites",
abstract = "Brother of the regulator of imprinted sites (BORIS) was previously described as a transcription factor for epigenetic reprogramming the expression of which is strictly confined to germ cells of adult testes but is aberrantly activated in the vast majority of neoplasiic cells. Considering the critical role of BORIS in cancerogenesis and the fact that its expression pattern may preclude thymic tolerance, we generated DNA- and protein-based mouse BORIS antitumor vaccines using a non-DNA-binding version of the BORIS molecule. Clinical use of BORIS as a vaccine Ag would require that certain safety concerns be met. Specifically, administration of the functional BORIS protein would hypothetically pose a risk of BORIS accelerating the progression of cancer. To alleviate such safety concerns, we have developed vaccines based on the BORIS molecule lacking the DNA-binding zinc fingers domain. To enhance anti-BORIS cellular immune responses, we used a standard molecular adjuvant approach. It consisted of plasmids encoding murine IL-12 and IL-18 for a DNA-based vaccine and conventional Th1 type adjuvant, Quil A, for a protein-based vaccine. Both DNA- and protein-based vaccines induced Ag-specific CD4+ T cell proliferation with Th1 and Th2 cytokine profiles, respectively. Protein-based, but not DNA-based, BORIS vaccine induced a significant level of Ab production in immunized animals. Importantly, potent anticancer CD8+-cytotoxic lymphocytes were generated after immunization with the DNA-based, but not protein-based, BORIS vaccine. These cytolytic responses were observed across a wide range of different mouse cancers including mammary adenocarcinoma, glioma, leukemia, and mastocytoma.",
author = "Anahit Ghochikyan and Mikayel Mkrtichyan and Dmitri Loukinov and Gregory Mamikonyan and Pack, {Svetlana D.} and Nina Movsesyan and Ichim, {Thomas E.} and Cribbs, {David H.} and Lobanenkov, {Victor V.} and Agadjanyan, {Michael G.}",
year = "2007",
month = "1",
day = "1",
doi = "10.4049/jimmunol.178.1.566",
language = "English (US)",
volume = "178",
pages = "566--573",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites

AU - Ghochikyan, Anahit

AU - Mkrtichyan, Mikayel

AU - Loukinov, Dmitri

AU - Mamikonyan, Gregory

AU - Pack, Svetlana D.

AU - Movsesyan, Nina

AU - Ichim, Thomas E.

AU - Cribbs, David H.

AU - Lobanenkov, Victor V.

AU - Agadjanyan, Michael G.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Brother of the regulator of imprinted sites (BORIS) was previously described as a transcription factor for epigenetic reprogramming the expression of which is strictly confined to germ cells of adult testes but is aberrantly activated in the vast majority of neoplasiic cells. Considering the critical role of BORIS in cancerogenesis and the fact that its expression pattern may preclude thymic tolerance, we generated DNA- and protein-based mouse BORIS antitumor vaccines using a non-DNA-binding version of the BORIS molecule. Clinical use of BORIS as a vaccine Ag would require that certain safety concerns be met. Specifically, administration of the functional BORIS protein would hypothetically pose a risk of BORIS accelerating the progression of cancer. To alleviate such safety concerns, we have developed vaccines based on the BORIS molecule lacking the DNA-binding zinc fingers domain. To enhance anti-BORIS cellular immune responses, we used a standard molecular adjuvant approach. It consisted of plasmids encoding murine IL-12 and IL-18 for a DNA-based vaccine and conventional Th1 type adjuvant, Quil A, for a protein-based vaccine. Both DNA- and protein-based vaccines induced Ag-specific CD4+ T cell proliferation with Th1 and Th2 cytokine profiles, respectively. Protein-based, but not DNA-based, BORIS vaccine induced a significant level of Ab production in immunized animals. Importantly, potent anticancer CD8+-cytotoxic lymphocytes were generated after immunization with the DNA-based, but not protein-based, BORIS vaccine. These cytolytic responses were observed across a wide range of different mouse cancers including mammary adenocarcinoma, glioma, leukemia, and mastocytoma.

AB - Brother of the regulator of imprinted sites (BORIS) was previously described as a transcription factor for epigenetic reprogramming the expression of which is strictly confined to germ cells of adult testes but is aberrantly activated in the vast majority of neoplasiic cells. Considering the critical role of BORIS in cancerogenesis and the fact that its expression pattern may preclude thymic tolerance, we generated DNA- and protein-based mouse BORIS antitumor vaccines using a non-DNA-binding version of the BORIS molecule. Clinical use of BORIS as a vaccine Ag would require that certain safety concerns be met. Specifically, administration of the functional BORIS protein would hypothetically pose a risk of BORIS accelerating the progression of cancer. To alleviate such safety concerns, we have developed vaccines based on the BORIS molecule lacking the DNA-binding zinc fingers domain. To enhance anti-BORIS cellular immune responses, we used a standard molecular adjuvant approach. It consisted of plasmids encoding murine IL-12 and IL-18 for a DNA-based vaccine and conventional Th1 type adjuvant, Quil A, for a protein-based vaccine. Both DNA- and protein-based vaccines induced Ag-specific CD4+ T cell proliferation with Th1 and Th2 cytokine profiles, respectively. Protein-based, but not DNA-based, BORIS vaccine induced a significant level of Ab production in immunized animals. Importantly, potent anticancer CD8+-cytotoxic lymphocytes were generated after immunization with the DNA-based, but not protein-based, BORIS vaccine. These cytolytic responses were observed across a wide range of different mouse cancers including mammary adenocarcinoma, glioma, leukemia, and mastocytoma.

UR - http://www.scopus.com/inward/record.url?scp=33846003817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846003817&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.178.1.566

DO - 10.4049/jimmunol.178.1.566

M3 - Article

C2 - 17182597

AN - SCOPUS:33846003817

VL - 178

SP - 566

EP - 573

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -